Jaguar Health’s Canalevia-CA1 Receives Conditional Approval Renewal from the US FDA for Chemotherapy-Induced Diarrhea in Dogs
Shots:
- The US FDA has approved Jaguar’s application to renew the conditional approval of Canalevia-CA1 (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is made available across the US by multiple veterinary distributors incl. Chewy
- The renewal of conditional approval is valid until 21st Dec, 2024. Canalevia-CA1 received its initial conditional approval in Dec 2021 from the US FDA for CID in dogs through the MUMS pathway
- Canalevia-CA1 is an oral canine-specific formulation of Crofelemer extracted from the Croton lechleri tree. Additionally, Jaguar plans to conduct a clinical field study on Canalevia-CA1 for CID treatment in dogs, pending FDA approval on the study protocol
Ref: Accesswire | Image: Jaguar Health
Related News:- Jaguar Animal Health Reports an Availability of Canalevia-CA1 on Chewy for Chemotherapy-Induced Diarrhea in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
